CNS Demyelination with TNF-α Blockers
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bosch X, Ramos-Casals M. Monoclonal antibody therapy-associated neurologic disorders. Nat Rev Neurol. 2011;7(3):165–72.
Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopoulos M, Kilidireas C, Rombos A, et al. Demyelinating disease following anti-TNF-α treatment: a causal or coincidental association? Report of Four cases and review of the literature. Case Rep Neurol Med. 2013;671935.
Robinson W, Genovese M, Moreland L. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum. 2001;44(9):1977–83.
Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The role of tumor necrosis factor and receptors in models of multi organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Immunol Rev. 1999;169:175–94.
Caminero A, Comabella M, Montalban X. Tumor necrosis factor α (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol. 2011;234(1):1–6.
Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427–34.
Lim S, Constantinescu C, Lim SY, Constantinescu CS. TNF-α: a paradigm of paradox and complexity in multiple sclerosis and its animal models. Open Autoimmun J. 2010;2:160–70.
Brambilla R, Ashbaugh J, Magliozzi R, Dellarole A, Karmally S, Szymkowski D, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011;134(9):2736–54.
•• Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2–22. Probert L analyses the TNF-α receptor signaling mechanisms in the CNS and their underlying pathology, stressing its role in apoptosis and neuroprotection.
Kalliolias G, Ivashkiv L. TNF biology, pathogenic mechanisms, and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62.
Weiss G, Schaible U. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015;264(1):182–203.
Linkermann A, Stockwell B, Krautwald S, Anders H. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. 2014;14(11):759–67.
Nishioku T, Matsumoto J, Dohgu S, Sumi N, Miyao K, Takata F, et al. Tumor necrosis factor-α mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. J Pharmacol Sci. 2010;112(2):251–4.
Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-αlpha: structure, function, and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215–28.
Silva L, Ortigosa L, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817–33.
Scallon B, Cai A, Solowski N, Song X, Song X, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418–26.
Tristano A. Neurologic adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010;257(9):1421–31.
Machado M, Barbosa M, Almeida A, de Araújo V, Kakehasi A, Andrade E, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33(9):2199–213.
Alexis A, Strober B. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg. 2005;9(6):296–302.
Sánchez-Cano D, Callejas-Rubio J, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm. 2013;286857.
van Oosten B, Barkhof F, Truyen L, Boringa J, Bertelsmann F, von Blomberg B, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47(6):1531–4.
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53(3):457–65.
Committee, British Thoracic Society Standards of Care. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-αlpha treatment. Thorax. 2005;60(10):800–5.
Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20(6):1181–95.
Brown A, Staugaitis S, Wu A, Calabrese L. Central nervous system vasculitis complicating rheumatoid arthritis in a patient on a TNF inhibitor: a causal association? Case report and systematic review. J Vasc. 2:104.
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–51.
Zengin O, Onder M, Alkan S, Kimyon G, Hüseynova N, Demir Z, et al. Three cases of anti-TNF induced myositis and literature review. Rev Bras Reumatol. 2016. (English edition) Mar 6.
Bruzzese V, Marrese C, Scolieri P, Hassan C, Lorenzetti R, Zullo A. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF-α therapy? Int J Rheum Dis. 2015;18(3):375–6.
Mohan N, Edwards E, Cupps T, Oliverio P, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.
Körner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med. 1997;186(9):1585–90.
Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 1989;170(2):607–12.
Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med. 1991;325(7):467–72.
Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991;32(1):67–74.
Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995;37(1):82–8.
van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Adèr HJ, Polman CH. Increased production of tumor necrosis factor-α, and not of interferon-γ, preceding disease activity in patients with multiple sclerosis. Arch Neurol. 1998;55(6):793–8.
• Valentin-Torres A, Savarin C, Hinton DR, Phares TW, Bergmann CC, Stohlman SA. Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis. J Neuroinflamm. 2016;13:46. Valentin-Torres et al used transgenic mice mimicking progressive EAE and demonstrated that TNF-α production promotes CNS inflammation, increasing the subsequent disability. By blocking TNF-α, disease severity was ameliorated.
• Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M, David S. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron. 2014;83(5):1098–116. Kroner et al demonstrated that TNF-α hinders the M2 conversion both in vitro and in vivo in spinal cord injured mice, contributing to tissue damage and functional disability.
Kruglov AA, Lampropoulou V, Fillatreau S, Nedospasov SA. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol. 2011;187(11):5660–70.
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting J. TNF-α promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001;4(11):1116–22.
Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990;172(4):1193–200.
Murphy CA, Hoek RM, Wiekowski MT, Lira SA, Sedgwick JD. Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J Immunol. 2002;169(12):7054–62.
Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol. 1994;24(9):2040–8.
Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation, and autoimmunity. Eur J Immunol. 2006;36(10):2768–80.
Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488(7412):508–11.
Sedger LM, McDermott MF. TNF, and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants—past, present, and future. Cytokine Growth Factor Rev. 2014;25(4):453–72.
Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurologic adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54–8.
Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor-α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum. 2002;46(11):3107–8. author reply 3108–9.
Titelbaum DS, Degenhardt A, Kinkel R. Anti-tumor necrosis factor-α-associated multiple sclerosis. AJNR Am J Neuroradiol. 2005;26(6):1548–50.
Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol. 2006;33(7):1457–8.
Dubcenco E, Ottaway CA, Chen DL, Baker J. Neurologic symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol. 2006;18(5):565–6.
Toussirot E, Pertuiset E, Martin A, Melac-Ducamp S, Alcalay M, Grardel B, et al. Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. J Rheumatol. 2006;33(5):1027–8.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–52.
van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Dräger AM, Adèr HJ, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol. 1999;45(6):695–703.
• Miller PG, Bonn MB, Franklin CL, Ericsson AC, McKarns SC. TNFR2 deficiency acts in concert with gut microbiota to precipitate spontaneous sex-biased central nervous system demyelinating autoimmune disease. J Immunol. 2015;195(10):4668–84. Miller et al demonstrated that TNFR2 deficiency in transgenic mice results in CNS demyelination, with a female preponderance.
Bellesi M, Logullo F, Di Bella P, Provinciali L. CNS demyelination during anti-tumor necrosis factor α therapy. J Neurol. 2006;253(5):668–9.
•• Mausner-Fainberg K, Regev K, Kolb H, Vaknin-Dembinsky A, Karni A. Increased neutralization capacity of TNF-α in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-α receptors or anti-TNF-α autoantibody levels. J Neuroimmunol. 2015;286:83–5. Mausner-Fainberg et al compared the TNF-α neutralization capacity of 42 patients with RRMS and 20 age-matched controls. The TNF-α neutralization capacity was increased in RRMS patients and not correlated to the sera levels of sTNFRI, sTNFRII and ant-TNF-α antibodies.
Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69:1691–3.
Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med. 2005;118:515–20.
Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-Tumor Necrosis Factor-α therapy. Ann Rheum Dis. 2007;66(9):1255–8.
Bruè C, Mariotti C, Rossiello I, Saitta A, Giovannini A. Demyelinizing neurologic disease after treatment with tumor necrosis factor-α antagonists. Case Rep Ophthalmol. 2016;7(2):345–53.
Defty H, Sames E, Doherty T, Hughes R. Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis. Case Rep Rheumatol. 2013;2013:728371.
Ryu YS, Park SH, Kim JM, Kim EJ, Lee J, Kwok SK, et al. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol Int. 2012;32(11):3481–5.
Kameda T, Dobashi H, Kittaka K, Susaki K, Hosomi N, Deguchi K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol. 2008;18(4):399–402.
Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007;34(1):239–40. Discussion 240.
Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013;32(2):271–5.
Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol. 2006;25(6):929–33.
Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33(6):1202–4.
Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol. 2008;37(5):397–9.
Kunzmann S, Warmuth-Metz M, Girschick HJ. Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol. 2005;34(1):76–8.
Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009;45(2):55–7.
Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. 2012;2(3):145–7.
Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013;33(4):1101–3.
Davis SA, Johnson RR, Pendleton JW. Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. J Rheumatol. 2008;35(7):1469–70.
Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol. 2008;59(1/2):91–3.
Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303–6.
Solomon AJ. SRKMBD. Inflammatory neurologic disease in patients treated with tumor necrosis factor-α blockers. Mult Scler. 2011;17(12):1472–87.
Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK. Cerebral MRI lesions and anti-tumor necrosis factor-α therapy. J Neurol. 2008;255 Suppl 6:109–14.
Hare NC, Hunt DP, Venugopal K, Ho GT, Beez T, Lees CW, et al. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. QJM. 2014;107(1):51–5.
Bradshaw MJ, Mobley BC, Zwerner JP, Sriram S. Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol Neuroinflamm. 2016;3(2), e205.
Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043–51.
Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010;62(11):3191–5.
Graff-Radford J, Robinson MT, Warsame RM, Matteson EL, Eggers SD, Keegan BM. Progressive multifocal leukoencephalopathy in a patient treated with etanercept. Neurologist. 2012;18(2):85–7.
Cereda CW, Zecca C, Mazzucchelli L, Valci L, Staedler C, Bassetti CL, et al. Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Mult Scler. 2013;19(6):820–3.
Mercieca C, Vella N, Borg AA. Demyelination during anti-TNF-α therapy for ankylosing spondylitis. Mod Rheumatol. 2012;22(2):303–7.
Felekis T, Katsanos K, Christodoulou D, Asproudis I, Tsianos EV. Reversible bilateral optic neuritis after infliximab discontinuation in a patient with Crohn's disease. J Crohns Colitis. 2009;3(3):212–4.
Ouakaa-Kchaou A, Gargouri D, Trojet S, Hefaiedh R, Elloumi H, Kochlef A, et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease. J Crohns Colitis. 2009;3(2):131–3.
Pikkel J. Possible link between infliximab and optic neuritis. Isr Med Assoc J. 2008;10(6):477–8.
Mumoli N, Niccoli G, Scazzeri F, Picchietti S, Greco A, Cei M. Infliximab-induced retrobulbar optic neuritis. QJM. 2007;100(8):531.
Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):283–7.
• Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C. Extensive and severe CNS demyelination associated with golimumab therapy. J Neurol. 2016;263(9):1869–71. Maillart et al report the first severe case of CNS demyeination in a 44-year-old woman with PsA treated with golimumab.
•• Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurologic adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16(3):R125. Kaltsonoudis et al prospectively studied eligible patients for anti-TNF-α therapy. Neurologic examination, brain and CSC MRI and neurophysiological testing was performed prior to treatment initiation. 3 of the 75 patients suffered from demyelination.
Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011;41(3):524–33.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.
Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000;43(2):243.
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–93.
•• Nyboe Andersen N, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor blockers. JAMA Intern Med. 2015;175(12):1990–2. This population based cohort study by Andersen et al, used the Danish Civil Registration System in order to identify IBD patients exposed to anti-TNF-α patients (4504) and matched unexposed patients (16.429). A possible 2-fold relative risk but a low absolute risk of CNS demyelination was suggested.
Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889–94.
Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, et al. The safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29(3):286–97.
Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H, Koch-Henriksen N, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler. 2008;14(6):823–9.
Kimura K, Hunter SF, Thollander MS, Loftus Jr EV, Melton III LJ, O'Brien PC, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000;75(8):802–6.
Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129(3):819–26.
Singh S, Kumar N, Loftus EV, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013;19:864–72.
Stovicek J, Liskova P, Lisy J, Hlava S, Keil R. Crohn's disease: is there a place for neurologic screening? Scand J Gastroenterol. 2014;49(2):173–6.
Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6:604–10.
Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol. 1998;16:1505–11.